Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease
Von Hippel-Lindau (VHL) disease is a familial cancer syndrome caused by a germline mutation in the VHL tumor suppressor gene (OMIM 193300) . 1 The prevalence of pancreatic neuroendocrine tumors (PNETs) in VHL disease ranges from 9% to 17% and is characterized by a better prognosis compared with sporadic PNETs. 2, 3 Several risk factors for PNET metastasis in VHL disease have been reported 4 but have not been validated. We conducted a prospective study (NCT00062166) to evaluate the natural history of VHL disease-associated pancreatic lesions to determine what factors were associated with PNET phenotype and prognosis.
Methods | Patients were enrolled from January 1, 2010, to January 1, 2017, based on the following eligibility criteria: age of 12 years or older, a diagnosis of VHL disease based on germline VHL mutation or clinical criteria, 5 and a pancreatic manifestation of VHL disease. Pancreatic protocol (2-mm section) abdominal computed tomography and pelvis computed tomography with intravenous contrast material were performed annually or every 2 years in patients with solid or cystic pancreatic lesions, respectively. Each imaging study was assessed by at least 2 independent reviewers. The criteria for surgical resection of pancreatic solid lesions were reported previously.
2 Disease-free interval and progression-free interval were defined as the time from inclusion without PNET and with no tumor growth (>5 mm and >20%), respectively. Patients diagnosed with VHL disease underwent genetic testing for mutations in the 3 coding exons and exon-intron boundaries of the VHL gene and for partial or complete deletion or duplication of the VHL gene in Clinical Laboratory Improvement Amendments-approved laboratories. 6 This study was approved by the institutional review board of the National Cancer Institute, and written informed consent was obtained from all patients enrolled in the study. All data were deidentified. (Table) .
Patients with a greatest tumor diameter less than 1.2 cm had a 100% negative predictive value for developing metastasis and requiring a surgical intervention during follow-up, whereas patients with a tumor diameter greater than 3.0 cm had a high risk of metastatic disease on univariate (hazard ratio [HR], 8.6; 95% CI, 2.1-34.9; P = .003) and multivariable analyses (HR, 8.6 ; 95% CI, 1.7-43.2; P = .009).
Among patients with a PNET diameter of 1.2 cm or greater and 3 cm or less, only those with a VHL missense mutation developed metastatic disease during follow-up (5 [12.5%] vs 0 patients with missense vs other type of VHL gene mutation; logrank test, P = .04). Patients with a VHL missense mutation had a higher rate of requiring a surgical intervention compared with other mutation types(16 [40.0%] with missense vs 5 [16.1%] with other VHL gene mutation type; log-rank test, P = .04), and patients with a VHL gene mutation located in exon 3 vs exon 1 or 2 had a higher rate of requiring a surgical intervention during follow-up (13 [44.8%] vs 8 patients [23.5%], P = .02). Patients with a missense VHL mutation or any mutation type in exon 3 had a higher rate of surgical intervention compared with other VHL genotypes on univariate (HR, 9.2; 95% CI, 1.2-68.7; P = .03) and multivariable analyses (HR, 8.8; 95% CI, ; P = .04).
Discussion | Our study findings support an evidence-based algorithm for risk stratification and surveillance of patients with VHL-associated pancreatic lesions (Figure) . Such an approach would provide precision medicine for patients with VHL disease-associated pancreatic lesions based on VHL genotype and tumor size. These results should be validated in future studies because of the rate of metastatic disease observed in our cohort. Anatomical imaging was pancreas protocol computed tomography with an early arterial phase. Of 9 patients with metastatic disease, 3 had a largest lesion diameter of greater than 3 cm, 6 had smaller lesion diameters; of these 6 patients, 5 had a missense VHL gene mutation and 1 did not have a determined genotype. PNET indicates pancreatic neuroendocrine tumor. Methods | Patients with a new diagnosis of clinical stage IV melanoma were identified using the National Cancer Database, an oncology outcomes database representing patients from more than 1500 hospitals nationwide. 6 The primary outcome of interest was overall survival (OS), which was estimated using the Kaplan-Meier method after categorizing patients by year of diagnosis. The OS among a contemporary cohort (diagnosed from 2011 to 2012) was compared with the OS of those in historical cohorts (diagnosed from 2004 to 2008 and from 2009 to 2010) . Statistical analysis was performed in Stata, version 14 (StataCorp LLC). Two-sided P < .05 was considered statistically significant. This study was reviewed and approved by the institutional review board of the University of Pennsylvania. Patient informed consent was waived as the national data set used in this study contained deidentified data, which make contacting individual patients impossible.
